Search results
Seven things we learned from Sir Salman Rushdie’s memoir
The Telegraph via Yahoo News· 4 days agoIn his memoir Knife, the author says his greatest fear is blindness. Having lost one eye in the...
Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com
ETF DAILY NEWS· 2 days agoStockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note published on Tuesday. The brokerage issued a sell rating on the biopharmaceutical ...
Kenneth T. Mills Sells 15,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) Stock
ETF DAILY NEWS· 17 hours agoREGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) CEO Kenneth T. Mills sold 15,000 shares of the business’s stock in a transaction on Monday, April 15th. Following the transaction, the chief executive ...
Cognition Therapeutics (NASDAQ:CGTX) and Black Diamond Therapeutics (NASDAQ:BDTX) Head to Head...
ETF DAILY NEWS· 2 days agoCognition Therapeutics (NASDAQ:CGTX – Get Free Report) and Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) are both small-cap medical companies, but which is the superior investment ...
Skye Bioscience (NASDAQ:SKYE) Now Covered by Oppenheimer
ETF DAILY NEWS· 4 days agoOppenheimer assumed coverage on shares of Skye Bioscience (NASDAQ:SKYE – Free Report) in a research...
Analysts Set Oculis Holding AG (NASDAQ:OCS) Target Price at $29.29
ETF DAILY NEWS· 7 days agoOculis Holding AG (NASDAQ:OCS – Get Free Report) has been given an average rating of “Buy” by the nine brokerages that are currently covering the firm, Marketbeat.com reports. Nine research ...
Salman Rushdie: I dreamt about being stabbed just before the attack
Daily Telegraph· 4 days agoIn August 2022, two days before he was due to appear at an event in Chautauqua, a small town in...
3 Affordable Pharma Stocks to Buy for Portfolio Gains | Entrepreneur
Entrpreneur· 7 days agoThe pharmaceutical market is anticipated to grow substantially in the upcoming years, owing to technological innovation and rising demand for personalized medicines. To that end, affordable ...
Apellis Pharmaceuticals (NASDAQ:APLS) Given New $57.00 Price Target at Wedbush
ETF DAILY NEWS· 16 hours agoApellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its target price lowered by Wedbush from $67.00 to $57.00 in a research report report published on Wednesday morning, Benzinga reports ...
Short Interest in Adverum Biotechnologies, Inc. (NASDAQ:ADVM) Grows By 37.2%
ETF DAILY NEWS· 6 days agoAdverum Biotechnologies, Inc. (NASDAQ:ADVM – Get Free Report) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 890,000 shares, a growth of ...